Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ziltivekimab · 8 trials · 11 indications
Change in percent atheroma volume (PAV) as determined by greyscale intravascular ultrasound (IVUS) in matched regions of interest. Theoretical change is between -100% to +100%. Typical range around -2% to +2%. A lower (more negative) change in PAV is better.
Percentage (%).
Measured in months.
Measured as score (score on scale; range; 0-100). The KCCQ is a disease-specific health status instrument composed of 23 items that quantify the domains of physical limitation, symptoms, self-efficacy, social limitation, and health-related quality of life limitation from heart failure. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. CSS scores range from 0 to 100 and lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life.
Measured in months.
Percent change in hs-CRP levels from baseline (average of the hs-CRP value prior to the administration of study drug) to the end of treatment (average of Week 10 and Week 12) is presented. Baseline was defined as the average of all hs-CRP values prior to the first administration of study drug at day 1 and end of treatment was defined as the average of hs-CRP values at week 10 and week 12.
Percent change from baseline in hs-CRP levels at week 13 are presented.
Nanograms per millilitre\*days (ng/mL\*days)
| Arm | Type | Description |
|---|---|---|
| Ziltivekimab Arm | EXPERIMENTAL | Participants will receive Ziltivekimab subcutaneously once per month |
| Placebo Arm | PLACEBO_COMPARATOR | Participants will receive placebo subcutaneously once per month |
| Ziltivekimab dose level 1 + standard of care (SOC) | EXPERIMENTAL | Participants receive dose level 1 of ziltivekimab along with standard of care (SOC) subcutaneously once monthly for 12 months. |
| Placebo + SOC | PLACEBO_COMPARATOR | Participants receive a placebo along with standard of care (SOC) subcutaneously once monthly for 12 months. |
| Ziltivekimab | EXPERIMENTAL | Participants will receive an initial loading dose of ziltivekimab Dose 1 subcutaneously (s.c.) as early as possible after invasive procedure, and latest within 36 hours of hospitalisation for ST-elevation myocardial infarction (STEMI) and within 48 hours of hospitalisation for non-ST-elevation myocardial infarction (NSTEMI), followed by ziltivekimab Dose 2 s.c. once-monthly during the treatment period (estimated up to 2 years) added to standard of care. |
| Placebo ziltivekimab | EXPERIMENTAL | Participants will receive placebo matched to ziltivekimab at an initial loading dose subcutaneously (s.c.) as early as possible after invasive procedure, and latest within 36 hours of hospitalisation for STEMI and latest within 48 hours of hospitalisation for NSTEMI, followed by placebo matched to ziltivekimab s.c. once-monthly during the treatment period (estimated up to 2 years) added to standard of care. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to ziltivekimab administered s.c. once-monthly and added to standard of care for 12 months. |
| Ziltivekimab 15 mg | EXPERIMENTAL | Participants will receive ziltivekimab 15 mg for 12 weeks. |
| Ziltivekimab 30 mg | EXPERIMENTAL | Participants will receive ziltivekimab 30 mg for 12 weeks. |
| Placebo (ziltivekimab) | PLACEBO_COMPARATOR | Participants will receive placebo (ziltivekimab) for 12 weeks. |
| Ziltivekimab 7.5 mg | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Ziltivekimab | DRUG | Ziltivekimab is administered subcutaneously (i.e., under the skin) once per month added to standard of care. |
| Placebo | DRUG | Placebo is administered subcutaneously (i.e., under the skin) once per month added to standard of care. |
| Ziltivekimab Placebo | DRUG | Participants will receive placebo matched to ziltivekimab subcutaneously. |
| Placebo (ziltivekimab) | DRUG | Administered s.c. once every 4 weeks for 12 weeks |
Key Inclusion Criteria: * Informed consent obtained before any study-related activities. * Age 18 years or above at the time of providing informed consent. * Acute myocardial infarction, with at least one coronary segment (culprit lesion) treated with PCI. * At least two major native coronary arter...
Ziltivekimab is an investigational small molecule developed by Novo Nordisk A/S for cardiovascular conditions linked to inflammation. It is being studied in chronic kidney disease, coronary artery disease, heart failure, and after acute myocardial infarction. It is not yet approved and remains in Phase 3 clinical development.
Ziltivekimab targets interleukin-6 (IL6) and acts as an inhibitor of this inflammatory cytokine. By inhibiting IL6 signaling, the drug is designed to reduce the systemic inflammation that contributes to cardiovascular risk in the patient populations being studied.
Ziltivekimab is being developed by Novo Nordisk A/S, which trades under the ticker NVO. Novo Nordisk is the sponsor of the Phase 3 clinical program evaluating the drug across cardiovascular and kidney-related indications.
Ziltivekimab is in Phase 3 clinical development. It is investigational and has not been approved by the FDA or any other regulatory agency. The Phase 3 program includes randomized, double-blind, controlled trials with a combined planned enrollment of approximately 10,000 participants.
Ziltivekimab is being evaluated in several Phase 3 trials, including ARTEMIS (NCT06118281) in people with a heart attack, NCT06200207 in heart failure with inflammation, NCT07301034 in myocardial infarction, and NCT07276282 in coronary atherosclerotic burden after acute myocardial infarction. These studies are recruiting or active and not recruiting.
Ziltivekimab is being studied for chronic kidney disease and chronic kidney disease with systemic inflammation, where elevated IL6-driven inflammation is thought to contribute to cardiovascular risk. It is an investigational therapy in Phase 3 testing and is not approved for use in chronic kidney disease or any other indication.